Therapix IPO on NASDAQ Could Catapult It into the Big Leagues

Source:   ()
Therapix Biosciences launches its IPO on NASDAQ on Wednesday, March 22, under the trading symbol TRPX. The Tel Aviv-based company specializing in the development and commercialization of cannabinoid-based treatments has a drug for Tourette Syndrome in Phase 2a trials and is additionally developing a drug for mild cognitive impairment. The IPO helps put it on a path to join much larger companies developing cannabinoid-based drugs. read more >

RepliCel's Phase 1 Trial for Hair Loss Completed Successfully

Source:   ()
RepliCel's successful conclusion of its Phase 1 trial for hair loss sets it up for the next steps in the drug's development. read more >

3D Signatures' Disruptive Technology Moving Ahead for Prostate Cancer and Hodgkin's Lymphoma

Source:   ()
3D Signatures continues to advance its cutting-edge technology for prostate cancer liquid biopsies and Hodgkin's lymphoma tests. read more >

Stellar Biotechnologies (SBOT:NASDAQ) Inks Multiyear KLH Supply Agreement with Amaran Biotechnology; Stellar Up 13% on News

Source: The Life Sciences Report  (03/02/2017)
Stellar Biotechnologies (SBOT:NASDAQ) Inks Multiyear KLH Supply Agreement with Amaran Biotechnology; Stellar Up 13% on News
Stellar Biotechnologies and Amaran Biotechnology have entered into an exclusive agreement where Stellar will supply KLH to the biopharmaceuticals manufacturer. read more >

Stellar Biotechnologies (SBOT:NASDAQ) Could Rise with KLH Vaccine Trial Success

Source: Jason McCarthy for The Life Sciences Report  (03/01/2017)
Stellar Biotechnologies (SBOT:NASDAQ) Could Rise with KLH Vaccine Trial Success
Several KLH-based vaccines are in trials for indications as varied as breast cancer and lupus, and clinical success could propel Stellar Biotechnologies, which is the only provider of KLH that has its own aquaculture facilities, says Jason McCarthy, an equity research analyst with Maxim Securities. Maxim currently has a price target of $4 on Stellar and the stock currently trades at around $1.65. read more >

Major Funds Betting On Trump Sector

Contributed Opinion
Source: Tom Beck for The Life Sciences Report  (02/25/2017)
Major Funds Betting On Trump Sector
Donald Trump's presidency is a real nitro boost for the future of the biotech sector in the U.S., says Tom Beck, editor of Portfolio Wealth Global. read more >

Buckle Up: Inflation at 58-Month High

Contributed Opinion
Source: Lior Gantz for The Gold Report  (02/23/2017)
Buckle Up: Inflation at 58-Month High
The stage has been set for high levels of uncertainly, and with uncertainty comes opportunities in commodities, posits Lior Gantz, editor of Wealth Research Group, who also sees opportunities in disruptive technologies in the medical arena. read more >
Expert Investing Ideas

"INO's revenues and R&D were slightly above our projections."

–Charles Duncan, Piper Jaffray & Co.


SCOTTSDALE CAPITAL CONFERENCE  in SCOTTSDALE, AZ
NASDAQ Biotech ARCA Pharmaceutical

Viveve Medical Posts Record Revenues and Analysts Foresee Continued Growth

Source: The Life Sciences Report  (02/22/2017)
Viveve Medical Posts Record Revenues and Analysts Foresee Continued Growth
As Viveve Medical ramped up its U.S. sales force, reported record earnings, increased the number of countries that have given regulatory approval and saw the results of its VIVEVE I clinical study published in the Journal of Sexual Medicine, a trio of analysts took notice. read more >
Management Q&A: View from the Top

RXi-MirImmune Merger Aims to Unlock Value Through Groundbreaking Technology

Managment Q&A: View from the Top
Source: The Life Sciences Report  (02/22/2017)
RXi-MirImmune Merger Aims to Unlock Value Through Groundbreaking Technology
RXi Pharmaceuticals' proprietary self-delivering RNAi (sd-rxRNA) platform offers efficient delivery to cells ex vivo, an application with tremendous potential in immuno-oncology. It's no surprise then that RXi has acquired MirImmune, a company that has been focusing on the next generation of immunotherapies for the treatment of cancer. In this interview with The Life Sciences Report, Geert Cauwenbergh, RXi's President and CEO; Alexey Eliseev, Chief Business Officer; and Pam Pavco, Chief Development Officer, discuss their technologies, the merger and why they believe that in 10 years pure chemotherapy could be relegated to the treatment of last resort. read more >

Investing in Life Sciences Under the Trump Presidency

Contributed Opinion
Source: Kristin McFarland for The Life Sciences Report  (02/16/2017)
Investing in Life Sciences Under the Trump Presidency
Stocks in all areas of life sciences including biotech to pharma have been on a roller coaster since Donald Trump won the election in November. Wealth advisor Kristin McFarland discusses the big picture for pharmaceutical investment under the new administration. read more >

Regeneus Hits the Fast Track with Major Japanese Partnership

Source: The Life Sciences Report  (02/08/2017)
Regeneus Hits the Fast Track with Major Japanese Partnership
Regeneus, an Australian regenerative medicine company, has entered into a collaboration with a major Japanese firm to manufacture its stem cell therapy Progenza, a move that may accelerate approval and that has a pair of analysts optimistic about the company's future. read more >
Biotech Watchlist 2017